ChemSpider 2D Image | Rasagiline mesylate | C13H17NO3S

Rasagiline mesylate

  • Molecular FormulaC13H17NO3S
  • Average mass267.344 Da
  • Monoisotopic mass267.092926 Da
  • ChemSpider ID2314552

  • defined stereocentres - 1 of 1 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(1R)-2,3-Dihydro-N-2-propynl-1H-inden-1-amine methanesulfonate
(1R)-N-(2-Propyn-1-yl)-1-indanamine methanesulfonate (1:1) [ACD/IUPAC Name]
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate (1:1)
(1R)-N-(Prop-2-yn-1-yl)indan-1-amine methanesulfonate (1:1)
(1R)-N-prop-2-yn-1-yl-2,3-dihydro-1H-inden-1-amine methanesulfonate
161735-79-1 [RN]
1H-Inden-1-amine, 2,3-dihydro-N-2-propyn-1-yl-, (1R)-, methanesulfonate (1:1) [ACD/Index Name]
1H-inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate (1:1)
Acide méthanesulfonique - (1R)-N-(2-propyn-1-yl)-1-indanamine (1:1) [French] [ACD/IUPAC Name]
acide méthanesulfonique - (1R)-N-prop-2-yn-1-yl-2,3-dihydro-1H-indén-1-amine (1:1)
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

TVP-1012 [DBID]
D02562 [DBID]
TVP 1012 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      Biochemicals & small molecules/Antagonists & inhibitors Hello Bio HB1784
      Enzymes Tocris Bioscience 4308
      Enzymes/Oxidase/Monoamine Oxidase/MAO-B Hello Bio HB1784
      Monoamine Oxidase Tocris Bioscience 4308
      Monoamine Oxidase MedChem Express HY-14605
      Nueronal Signaling; MedChem Express HY-14605
      Oxygenases/Oxidases Tocris Bioscience 4308
      Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. MedChem Express http://www.medchemexpress.com/rasagiline-mesylate.html
      Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. ;Target: Monoamine Oxidase (MAO)-BRasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding h MedChem Express HY-14605
      Selective irreversible MAO-B inhibitor. Displays antiParkinsonian activity; exhibits neuroprotective and antiapoptotic activity against several neurotoxins in cell culture. Tocris Bioscience 4308
      Selective irreversible MAO-B inhibitor. Displays neuroprotective, anti-apoptosis and anti-parkinsonian activity. Hello Bio HB1784
      Selective, irreversible MAO-B inhibitor Tocris Bioscience 4308
      Selective, irreversible MAO-B inhibitor Hello Bio HB1784

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement